title: [Expert statement for augmentation therapy in patients with alpha-1 antitrypsin deficiency].
abstract: Augmentation therapy in Alpha-1 Antitrypsin Deficiency aims to reduce the progression of lung emphysema, to reduce exacerbation frequency, and to improve quality of life. This expert statement briefly summarizes the most important treatment studies performed in patients with Alpha-1 Antitrypsin Deficiency and severe lung emphysema. Indications and contraindications for long-term intravenous augmentation therapy with human Alpha-1 Antitrypsin are derived from the available study results. Safety issues and the controversies of this topic are discussed in detail.
authors.affiliation: Klinikum St. Georg gGmbH Leipzig, Robert-Koch-Klinik.
authors.forename: T
authors.initials: T
authors.lastname: Köhnlein
authors.affiliation: Wilhelminenspital Wien, 2. Medizinische Abteilung/Lungenabteilung.
authors.forename: K
authors.initials: K
authors.lastname: Schmidt-Scherzer
authors.affiliation: Universitätsklinikum Marburg, Klinik für Innere Medizin, Schwerpunkt Pneumologie.
authors.forename: T
authors.initials: T
authors.lastname: Greulich
authors.affiliation: Universitätsklinikum des Saarlandes, Innere Medizin V - Pneumologie, Allergologie, Beatmungs- und Umweltmedizin, Homburg/Saar.
authors.forename: R
authors.initials: R
authors.lastname: Bals
mesh_terms: D056947:Enzyme Replacement Therapy; D019317:Evidence-Based Medicine; D006801:Humans; D007261:Infusions, Intra-Arterial; D011656:Pulmonary Emphysema / Q000175:diagnosis / Q000209:etiology*; D015842:Serine Proteinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome; D000515:alpha 1-Antitrypsin / Q000008:administration & dosage* / Q000009:adverse effects; D019896:alpha 1-Antitrypsin Deficiency / Q000150:complications* / Q000175:diagnosis
chemical_list: D015842:Serine Proteinase Inhibitors; D000515:alpha 1-Antitrypsin